checkAd

     113  0 Kommentare Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals

    Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts. The company’s ESG strategy is embedded in its mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402638203/en/

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Bristol-Myers Squibb!
    Long
    37,06€
    Basispreis
    0,34
    Ask
    × 11,37
    Hebel
    Short
    45,22€
    Basispreis
    0,44
    Ask
    × 8,50
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    “For more than 130 years, BMS has enabled positive change for our patients around the world. As we navigate an increasingly complex global landscape, our ESG strategy has never been more important to driving long-term business value and fulfilling our purpose,” said Christopher Boerner, Ph.D., Board Chair & Chief Executive Officer, Bristol Myers Squibb. “We recognize ESG is a journey of continuous improvement, and our entire team is committed to advancing sustainability.”

    In 2023, BMS conducted a global ESG materiality assessment to understand evolving stakeholder views and ensure its business priorities reflect the rapidly changing landscape. These insights enabled the company to evolve its ESG strategy, focusing on three key pillars: advancing patient health around the world; expanding the boundaries of science; and fostering a high-performing and inclusive global workforce. At the same time, BMS will continue to amplify its strong performance across material topics such as patient safety and product quality, ethics and conduct, as well as environmental sustainability.

    Highlights from the ESG Report:

    Advancing Patient Health Around the World

    • Advanced tailored access programs in low- and middle-income countries (LMICs) to help improve access to BMS’ innovative portfolio. Through new pathways, BMS has expanded access to 12 transformative products for patients across more than 80 LMICs. We have established an aspirational goal that 100% of late-stage assets will have access plans in 2024 and a commitment to reach more than 208,000 patients in LMICs by 2033.
    • Progressed health equity efforts through 277 grants and donations, totaling $19.4M.

    Expanding the Boundaries of Science

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts. The company’s ESG strategy is …

    Artikel zu den Werten

    Schreibe Deinen Kommentar

    Disclaimer